[et_pb_section admin_label=”section”]
[et_pb_row admin_label=”row”]
[et_pb_column type=”4_4″][et_pb_text admin_label=”Text”]Spotrate Market News
New York NY – Feb 25, 2026 — Spotrate Market News — The global immuno-oncology market is projected to expand significantly over the next decade, supported by advances in checkpoint inhibitors, CAR-T cell therapies, and next-generation cancer vaccines. Industry research indicates the immuno-oncology segment could grow from approximately $65 billion in 2025 to more than $170 billion by 2032.
The broader oncology market is also forecast to expand materially, with estimates suggesting total market value could exceed $748 billion by 2035. Within that landscape, the global oncology drugs market is projected to reach approximately $335.2 billion by 2033, growing at a compound annual growth rate of 7.2%.
Against this backdrop, Oncolytics Biotech Inc. (NASDAQ: ONCY) announced that it will prioritize registrational programs in anal and colorectal cancer following completion of enrollment in its GOBLET gastrointestinal study. The company stated that sufficient clinical and translational data were generated to define a potential regulatory pathway for pelareorep.
According to management, Cohort 4 data from GOBLET supports pursuing a registrational strategy for pelareorep in second-line and later squamous cell anal cancer. Oncolytics expects to meet with the U.S. Food and Drug Administration (FDA) in mid-April to align on study design and regulatory considerations. The company believes that a study enrolling fewer than 100 patients may be sufficient in this rare cancer indication, subject to regulatory agreement.
Pelareorep previously received Fast Track Designation from the FDA for second-line KRAS-mutant microsatellite-stable (MSS) metastatic colorectal cancer. Clinical data reported by the company demonstrated a 33% response rate when pelareorep was combined with chemotherapy and Avastin®, compared to approximately 10% reported historically for chemotherapy and Avastin® alone. Median overall survival reached 27 months versus 11.2 months under benchmark standard therapy.
KRAS-mutant MSS colorectal cancer remains a difficult-to-treat population with limited options following first-line treatment failure. The company estimates the global second-line treatment opportunity in this setting to range between $3 billion and $5 billion annually. Oncolytics indicated that a controlled study is expected to initiate in March, with interim data anticipated before year-end 2026.
In anal cancer, the company reported response rates of 29% in third-line patients and 30% in second-line or later patients. Median duration of response was approximately 17 months in third-line patients.
In related industry developments, ImmunityBio (NASDAQ: IBRX), CRISPR Therapeutics (NASDAQ: CRSP), BioNTech (NASDAQ: BNTX), and Novocure (NASDAQ: NVCR) continue to advance programs across oncology and cell therapy platforms, reflecting ongoing investment and innovation within the sector.
Sources
- Immuno-Oncology Market Expansion Report — OpenPR
https://www.openpr.com/news/4395526/immuno-oncology-market-set-for-remarkable-expansion-as - Oncology Market Value Forecast — PharmiWeb
https://www.pharmiweb.com/press-release/2026-02-19/oncology-market-value-to-more-than-double-reaching-usd-74817-billion-by-2035 - Oncology Drugs Market Forecast — PR Newswire / Allied Market Research
https://www.prnewswire.com/news-releases/oncologycancer-drugs-market-to-reach-335-2-billion-by-2033-globally-at-7-2-cagr-allied-market-research-302683974.html
Media Contact
Editorial Inquiries:
editor@spotrate.io
Disclaimer
This communication is provided for informational purposes only and does not constitute investment advice, financial advice, or a recommendation to buy or sell securities. Spotrate is not a registered investment advisor or broker-dealer. Information is based on publicly available sources believed to be reliable; however, Spotrate makes no representation or warranty as to accuracy or completeness. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially. Readers should conduct independent research and consult with a qualified financial advisor before making investment decisions.[/et_pb_text][/et_pb_column]
[/et_pb_row]
[/et_pb_section]